Immune-modulating interventions in critically ill septic patients: Pharmacological options

Expert Review of Clinical Pharmacology

Volumn 4, Issue 4, 2011, Pages 491-501

  Toft, Palle ^a   Tønnesen, Else ^b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

critical illness; immune modulating interventions; mortality; sepsis

Indexed keywords

ANTITHROMBIN III; BENZODIAZEPINE DERIVATIVE; CD14 ANTIGEN; CLARITHROMYCIN; CORTICOSTEROID; CYTOFAB; DEXAMETHASONE; DROTRECOGIN; ERITORAN; ETOMIDATE; FLUDROCORTISONE; GR 2707730; GRANULOCYTE COLONY STIMULATING FACTOR; HEPARIN; HUMAN GROWTH HORMONE; HYDROCORTISONE; IMMUNOMODULATING AGENT; INSULIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; NITRIC OXIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RESATORVID; STEROID 11BETA MONOOXYGENASE; SURFACTANT; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADULT RESPIRATORY DISTRESS SYNDROME; ANTIBODY PRODUCTION; BLOOD CLOTTING; CREATININE BLOOD LEVEL; CRITICALLY ILL PATIENT; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOCRINE SYSTEM; GRAM NEGATIVE SEPSIS; GRANULOCYTE; HORMONE SYNTHESIS; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERGLYCEMIA; HYPERTENSION; HYPOTENSION; HYPOXIA; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOSTIMULATION; INFLAMMATION; INSULIN TREATMENT; LUNG INJURY; MACROPHAGE FUNCTION; MORTALITY; MULTIPLE ORGAN FAILURE; NEUTROPENIA; NONHUMAN; PERFUSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY FAILURE; REVIEW; SEPSIS; SEPTIC SHOCK; SURVIVAL TIME; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; VENTILATOR ASSOCIATED PNEUMONIA;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CRITICAL ILLNESS; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION MEDIATORS; PROTEIN C; SEPSIS;

EID: 79960396278     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.11.25     Document Type: Review

References (74)

1. Levy MM, Fink MP, Marshall JC et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit. Care Med. 31(4), 1250-1256 (2003). (Pubitemid 36444440)
2. Adrie C, Pinsky MR. The inflammatory balance in human sepsis. Intensive Care Med. 26(4), 364-375 (2000). (Pubitemid 30301516)
3. Toft P, Kehler D, Brandslund I, Tønnesen E. The immunological effects of continuous veno-venous haemodiafiltration in critically ill patients. Crit. Care 3(6), 159-165 (1999). (Pubitemid 30004544)
4. Toft P, Lillevang ST, Tonnesen E, Nielsen CH, Rasmussen JW. The redistribution of granulocytes following E. coli endotoxin induced sepsis. Acta Anaesthesiol. Scand. 38(8), 852-857 (1994). (Pubitemid 24375682)
5. Giannoudis PV, Smith RM, Perry SL, Windsor AJ, Dickson RA, Bellamy MC. Immediate IL-10 expression following major orthopaedic trauma: relationship to anti-inflammatory response and subsequent development of sepsis. Intensive Care Med. 26(8), 1076-1081 (2000).
6. Annane D, Sebille V, Troche G, Raphael JC, Gajdos P, Bellissant E. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 283(8), 1038-1045 (2000). (Pubitemid 30112218)
7. Opal S, Laterre PF, Abraham E et al. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a Phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Crit. Care Med. 32(2), 332-341 (2004). (Pubitemid 38234108)
8. Lee WL, Downey GP. Coagulation inhibitors in sepsis and disseminated intravascular coagulation. Intensive Care Med. 26(11), 1701-1706 (2000).
9. Sakr Y, Reinhart K, Vincent JL et al. Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Crit. Care Med. 34(3), 589-597 (2006).
10. De BD, Biston P, Devriendt J et al. Comparison of dopamine and norepinephrine in the treatment of shock. N. Engl. J. Med. 362(9), 779-789 (2010).
11. Sprung CL, Caralis PV, Marcial EH et al. The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N. Engl. J. Med. 311(18), 1137-1143 (1984). (Pubitemid 14012580)
12. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N. Engl. J. Med. 317(11), 653-658 (1987). (Pubitemid 17138189)
13. Watt I, Ledingham IM. Mortality amongst multiple trauma patients admitted to an intensive therapy unit. Anaesthesia 39(10), 973-981 (1984). (Pubitemid 15076641)
14. Cuthbertson BH, Sprung CL, Annane D et al. The effects of etomidate on adrenal responsiveness and mortality in patients with septic shock. Intensive Care Med. 35(11), 1868-1876 (2009).
15. Annane D, Sebille V, Charpentier C et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288(7), 862-871 (2002).
16. Sprung CL, Annane D, Keh D et al. Hydrocortisone therapy for patients with septic shock. N. Engl. J. Med. 358(2), 111-124 (2008).
17. Dellinger RP, Levy MM, Carlet JM et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit. Care Med. 36(1), 296-327 (2008).
18. Meduri GU, Headley AS, Golden E et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA 280(2), 159-165 (1998). (Pubitemid 28498389)
19. Steinberg KP, Hudson LD, Goodman RB et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N. Engl. J. Med. 354(16), 1671-1684 (2006).
20. Takala J, Ruokonen E, Webster NR et al. Increased mortality associated with growth hormone treatment in critically ill adults. N. Engl. J. Med. 341(11), 785-792 (1999). (Pubitemid 29420473)
21. Andersen S, Toft P, Tonnesen E. Immunological aspects of major accidental trauma with special reference to cytokines: a review. Placebo 2(4), 123-136 (2001).
22. Fisher CJ Jr, Dhainaut JF, Opal SM et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 271(23), 1836-1843 (1994). (Pubitemid 24169697)
23. Opal SM, Fisher CJ Jr, Dhainaut JF et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a Phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit. Care Med. 25(7), 1115-1124 (1997). (Pubitemid 27310249)
24. Abraham E, Wunderink R, Silverman H et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor ain patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-aMAb Sepsis Study Group. JAMA 273(12), 934-941 (1995).
25. Reinhart K, Wiegand-Lohnert C, Grimminger F et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit. Care Med. 24(5), 733-742 (1996).
26. Cohen J, Carlet J. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-ain patients with sepsis. International Sepsis Trial Study Group. Crit. Care Med. 24(9), 1431-1440 (1996). (Pubitemid 26313741)
27. Rice TW, Wheeler AP, Morris PE et al. Safety and efficacy of affinity-purified, anti-tumor necrosis factor-a, ovine fab for injection (CytoFab) in severe sepsis. Crit. Care Med. 34(9), 2271-2281 (2006). (Pubitemid 44260009)
28. Giamarellos-Bourboulis EJ, Pechre JC, Routsi C et al. Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin. Infect. Dis. 46(8), 1157-1164 (2008). (Pubitemid 351589897)
29. Wittebole X, Castanares-Zapatero D, Laterre PF. Toll-like receptor 4 modulation as a strategy to treat sepsis. Mediators Inflamm. 2010, 568396 (2010).
30. Rice TW, Wheeler AP, Bernard GR et al. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit. Care Med. 38(8), 1685-1694 (2010).
31. Bunnell E, Lynn M, Habet K et al. A lipid A analog, E5531, blocks the endotoxin response in human volunteers with experimental endotoxemia. Crit. Care Med. 28(8), 2713-2720 (2000).
32. Tidswell M, Tillis W, Larosa SP et al. Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis. Crit. Care Med. 38(1), 72-83 (2010).
33. Bennett-Guerrero E, Grocott HP, Levy JH et al. A Phase II, double-blind, placebo-controlled, ascending-dose study of Eritoran (E5564), a lipid A antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass. Anesth. Analg. 104(2), 378-383 (2007). (Pubitemid 46146745)
34. Dellinger RP, Tomayko JF, Angus DC et al. Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: results of a Phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial. Crit. Care Med. 37(11), 2929-2938 (2009).
35. Dhainaut JF, Tenaillon A, Hemmer M et al. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe Gram-negative bacterial sepsis: a Phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group. Crit. Care Med. 26(12), 1963-1971 (1998). (Pubitemid 29016675)
36. Gillan ER, Christensen RD, Suen Y, Ellis R, van de Ven C, Cairo MS. A randomized, placebo-controlled trial of recombinant human granulocyte colony-stimulating factor administration in newborn infants with presumed sepsis: significant induction of peripheral and bone marrow neutrophilia. Blood 84(5), 1427-1433 (1994).
37. Bilgin K, Yaramis A, Haspolat K, Tas MA, Gunbey S, Derman O. A randomized trial of granulocyte-macrophage colony-stimulating factor in neonates with sepsis and neutropenia. Pediatrics 107(1), 36-41 (2001). (Pubitemid 32055412)
38. Presneill JJ, Harris T, Stewart AG, Cade JF, Wilson JW. A randomized Phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. Am. J. Respir. Crit. Care Med. 166(2), 138-143 (2002). (Pubitemid 34765447)
39. Döcke WD, Randow F, Syrbe U et al. Monocyte deactivation in septic patients: restoration by IFN-g treatment. Nat. Med. 3(6), 678-681 (1997). (Pubitemid 27264980)
40. Eisele B, Lamy M, Thijs LG et al. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med. 24(7), 663-672 (1998). (Pubitemid 28393397)
41. Warren BL, Eid A, Singer P et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286(15), 1869-1878 (2001). (Pubitemid 33010239)
42. Jaimes F, De La Rosa G, Morales C et al. Unfractioned heparin for treatment of sepsis: a randomized clinical trial (The HETRASE Study). Crit. Care Med. 37(4), 1185-1196 (2009).
43. Novack V, Terblanche M, Almog Y. Do statins have a role in preventing or treating sepsis? Crit. Care 10(1), 113 (2006).
44. Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackam DG. Statins and sepsis: multiple modifications at multiple levels. Lancet Infect. Dis. 7(5), 358-368 (2007). (Pubitemid 46590065)
45. Thomsen RW, Hundborg HH, Johnsen SP et al. Statin use and mortality within 180 days after bacteremia: a population-based cohort study. Crit. Care Med. 34(4), 1080-1086 (2006).
46. Thomsen RW, Riis A, Kornum JB, Christensen S, Johnsen SP, Sorensen HT. Preadmission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 29,900 patients. Arch. Intern. Med. 168(19), 2081-2087 (2008).
47. Fernandez R, De Pedro VJ, Artigas A. Statin therapy prior to ICU admission: protection against infection or a severity marker? Intensive Care Med. 32(1), 160-164 (2006). (Pubitemid 43039392)
48. Schmidt H, Hennen R, Keller A et al. Association of statin therapy and increased survival in patients with multiple organ dysfunction syndrome. Intensive Care Med. 32(8), 1248-1251 (2006). (Pubitemid 44232422)
49. Kor DJ, Iscimen R, Yilmaz M, Brown MJ, Brown DR, Gajic O. Statin administration did not influence the progression of lung injury or associated organ failures in a cohort of patients with acute lung injury. Intensive Care Med. 35(6), 1039-1046 (2009).
50. Fogerty MD, Efron D, Morandi A, Guy JS, Abumrad NN, Barbul A. Effect of preinjury statin use on mortality and septic shock in elderly burn patients. J. Trauma 69(1), 99-103 (2010).
51. Bernard GR, Vincent JL, Laterre PF et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344(10), 699-709 (2001). (Pubitemid 32204987)
52. Vincent JL, Bernard GR, Beale R et al. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit. Care Med. 33(10), 2266-2277 (2005). (Pubitemid 41437481)
53. Abraham E, Laterre PF, Garg R et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N. Engl. J. Med. 353(13), 1332-1341 (2005). (Pubitemid 41362701)
54. Nadel S, Goldstein B, Williams MD et al. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre Phase III randomised controlled trial. Lancet 369(9564), 836-843 (2007). (Pubitemid 46365900)
55. Silva E, de Figueiredo LF, Colombari F. Prowess-shock trial: a protocol overview and perspectives. Shock 34(Suppl. 1), 48-53 (2010).
56. Anzueto A, Baughman RP, Guntupalli KK et al. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group. N. Engl. J. Med. 334(22), 1417-1421 (1996). (Pubitemid 26157436)
57. Kesecioglu J, Beale R, Stewart TE et al. Exogenous natural surfactant for treatment of acute lung injury and the acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 180(10), 989-994 (2009).
58. Lopez A, Lorente JA, Steingrub J et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit. Care Med. 32(1), 21-30 (2004). (Pubitemid 38125559)
59. Griffiths MJ, Evans TW. Inhaled nitric oxide therapy in adults. N. Engl. J. Med. 353(25), 2683-2695 (2005). (Pubitemid 41817717)
60. Lundin S, Mang H, Smithies M, Stenqvist O, Frostell C. Inhalation of nitric oxide in acute lung injury: results of a European multicentre study. The European Study Group of Inhaled Nitric Oxide. Intensive Care Med. 25(9), 911-919 (1999). (Pubitemid 29452535)
61. Greenman RL, Schein RM, Martin MA et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of Gram-negative sepsis. The XOMA Sepsis Study Group. JAMA 266(8), 1097-1102 (1991).
62. Ziegler EJ, Fisher CJ Jr, Sprung CL et al. Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N. Engl. J. Med. 324(7), 429-436 (1991).
63. McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. Ann. Intern. Med. 121(1), 1-5 (1994).
64. Werdan K, Pilz G, Bujdoso O et al. Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit. Care Med. 5(12), 2693-2701 (2007). (Pubitemid 350175763)
65. Kreymann KG, de HG, Nierhaus A, Kluge S. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit. Care Med. 35(12), 2677-2685 (2007). (Pubitemid 350175761)
66. Laupland KB, Kirkpatrick AW, Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit. Care Med. 35(12), 2686-2692 (2007). (Pubitemid 350175762)
67. van den Berghe G, Wouters P, Weekers F et al. Intensive insulin therapy in the critically ill patients. N. Engl. J. Med. 345(19), 1359-1367 (2001).
68. van den Berghe G, Schetz M, Vlasselaers D et al. Clinical review: intensive insulin therapy in critically ill patients: NICE-SUGAR or Leuven blood glucose target? J. Clin. Endocrinol. Metab. 94(9), 3163-3170 (2009).
69. van den Berghe G, Wilmer A, Hermans G et al. Intensive insulin therapy in the medical ICU. N. Engl. J. Med. 354(5), 449-461 (2006). (Pubitemid 43200296)
70. Brunkhorst FM, Engel C, Bloos F et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N. Engl. J. Med. 358(2), 125-139 (2008).
71. Preiser JC, Devos P, Ruiz-Santana S et al. A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study. Intensive Care Med. 35(10), 1738-1748 (2009).
72. Griesdale DE, de Souza RJ, van Dam RM et al. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. CMAJ 180(8), 821-827 (2009).
73. Finfer S, Chittock DR, Su SY et al. Intensive versus conventional glucose control in critically ill patients. N. Engl. J. Med. 360(13), 1283-1297 (2009).
74. Ospina-Tascon GA, Büchele LG, Vincent J-L. Multicenter, randomized, controlled trials evaluating mortality in intensive care: doomed to fail? Crit. Care. Med. 36, 1311-1322 (2008). (Pubitemid 351482683)